Mylan

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Pfizer's proposed deal with Mylan is complicated. But if you're a Pfizer shareholder, here's what you need to know.

3 Key Things to Know About How the Mylan-Upjohn Merger Affects Pfizer Shareholders

Mylan NV's  planned merger with Pfizer Inc's  off-patent branded drugs business may have boosted its share price on Monday, but one of its most pressing problems remains: shortages of its flagship EpiPen emergency allergy treatment.

Mylan deal puts future of its beleaguered EpiPen in spotlight

Pfizer (NYSE:PFE) today announced its plan to combine its generic drugs business with Mylan in a Reverse Morris Trust transaction. The combined entity could generate sales of over $20 billion by 2020, and Pfizer will hold a 57% stake in the new company, with Mylan holding the rest.

How Big Is Pfizer's Generic Drugs Business That It Plans To Merge With Mylan?

Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.

Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer

The drugmaker's revenue improved in the second quarter with new product launches, but higher spending weighed on its earnings.

Mylan's Mixed 2nd-Quarter Results Overshadowed by News of Its Upjohn Merger

Drugmaker Pfizer Inc. (NYSE:PFE) announced on Monday it is combining its off-patent drug business, which is called Upjohn, with Pittsburgh-based generic pharmaceutical giant Mylan NV (NASDAQ:MYL) in an all-stock deal, creating a new company.

Pfizer Inc to Combine Off-Patent Drug Business With Mylan NV

A new Mylan-Pfizer deal that will have the companies taking part in a merger agreement has MYL stock heading higher on Monday.
The post Mylan-Pfizer Deal: MYL Stock Soars on Off-Patent Drug Merger appeared first on InvestorPlace.

Mylan-Pfizer Deal: MYL Stock Soars on Off-Patent Drug Merger

Pfizer Inc  has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV , a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

Pfizer to spinoff, merge off-patent drugs unit with Mylan

A proposed combination with Pfizer's Upjohn unit is exciting Mylan shareholders.

Why Mylan Stock Is Jumping Today

Chipotle

Stocks were mixed on Wall Street Monday morning.

Stock Market News: Pfizer and Mylan Make a Deal; Chipotle Looks Tasty

Pfizer (PFE) beats estimates for second-quarter earnings but misses on sales. The company also lowers 2019 earnings and sales guidance.

Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan

Pfizer announced an all-stock plan Monday to combine its off-patent and generic drugs unit, Upjohn, with pharmaceutical company Mylan — sending Mylan stock flying as Pfizer stock stumbled.
The post Merger Fever Runs Hot In Pharma As Pfizer, Mylan Announce Matchup appeared first on Investor's Business Daily.

Merger Fever Runs Hot In Pharma As Pfizer, Mylan Announce Matchup

Drugmaker Pfizer Inc  has agreed to spin off its generic drugs business and combine it with Mylan , a move that leaves Pfizer with more profitable innovative drugs, including cancer drug Ibrance and pneumonia vaccine Prevnar.

Pfizer to merge generics unit with Mylan; seeks to sharpen cancer focus

Mylan N.V. (NASDAQ: MYL) released its second-quarter financial results before the markets opened on Monday.

What This Mylan-Pfizer Pharma Juggernaut Will Look Like

Shares of companies in the generic drugs business rallied Monday, after Mylan N.V. announced the deal to merge with Pfizer Inc.'s Upjohn.

Generic drug maker stocks rally after Mylan deal to merge with Pfizer's Upjohn

Mylan (MYL) delivered earnings and revenue surprises of 8.42% and 0.97%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Mylan (MYL) Q2 Earnings and Revenues Top Estimates

Mylan (NASDAQ: MYL) shares are trading higher after it announced the launch of a new company with Pfizer's (NYSE: PFE) Upjohn division.

Mylan, Pfizer's Upjohn To Merge And Create New Company

Mylan (NASDAQ: MYL) reported second-quarter earnings of $1.03 per share, which beat the analyst consensus estimate of 94 cents.

Mylan Reports Q2 Earnings Beat

Mylan N.V. MYL, +0.11% said that in connection with the deal to merge with Pfizer Inc.

Mylan CEO Heather Bresch to retire after deal to merge with Pfizer's Upjohn closes

Shares of Mylan N.V. MYL, +0.11% soared 24% in premarket trading Monday, after the generic drug maker announced a deal to merge with Pfizer Inc.

Mylan beats adjusted profit, revenue expectations

Mylan NV  said on Monday it would combine with Pfizer Inc's  off-patent branded and generic established medicines business to form a global generic drugmaker.

Mylan to combine with Pfizer's off-patent medicines unit

Shares of Mylan N.V. MYL, +0.11% soared 24% in premarket trading Monday, after the generic drug maker confirmed it was merging with Pfizer Inc.

Mylan's stock soars after deal to merger with Pfizer's Upjohn

The deal, expected to be announced Monday, will result in Pfizer shareholders owning most of the new company with Mylan's shareholders owning slightly more than 40%.

Pfizer plans combination of off-patent drug business with Mylan

Pfizer Inc  is in talks to merge its off-patent drugs business with Mylan NV  in a stock deal, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Pfizer in talks to merge off-patent drugs business with Mylan

Amneal Pharmaceuticals

Endo International

Teva Pharmaceutical

Pharmaceutical stocks Teva Pharmaceutical, Mylan, Endo and Amneal Pharmaceuticals may have to pay $8.5 billion in litigation costs surrounding the opioid epidemic, an analyst said Monday.

News for Mylan Stock (MYL)